Lab Tests and Supplements Wisely: What’s Useful, Uncertain, or Unnecessary?
Labs are a compass, not a diagnosis, and supplements belong only where they’re targeted — every marker and every pill should have a measurable goal and a checkpoint.
Lab tests and supplements can be useful—but only when targeted. Labs are a compass, not a diagnosis: a single marker without context can be misleading. Supplement effects are strongest when correcting documented deficiency; marketing-driven accumulation obscures real lifestyle effects and may cause drug interactions [100]. The “core list” principle: take only what has a measurable target, documented indication, and checkpoint.
Labs as a Compass
Routine lab parameters are often late signals of problems. Fasting blood glucose, for example, can remain normal even when significant insulin resistance[G] is present—because the pancreas compensates, maintaining glucose at normal levels with elevated insulin. Fasting insulin[G] and HOMA-IR[G] are therefore earlier and more accurate compass points. The HOMA-IR[G] formula: fasting insulin[G] (mIU/L) × fasting glucose (mmol/L) ÷ 22.5. Reference range: <1.5 normal insulin sensitivity[G]; 1.5–2.5 reduced sensitivity; >2.5 clinical insulin resistance[G]. Important: HOMA-IR[G] cutpoints depend on lab methodology, population, and age—values are always interpreted by the physician in full clinical context. This is one of the cheapest and most flexible metabolic markers you can order with any blood test.
CGM[G] (continuous glucose monitor) fits into this learning process: it is not a diagnostic tool but feedback—it shows how the body responds to a food, poor sleep, or a stressful day. This helps personalize diet but is not by itself a clinical decision basis.
Microbiota[G] testing should also be understood this way: snapshots that only gain meaning with metabolic and clinical data (see Chapter 20). Microbiota[G] status is more a monitoring tool than a standalone diagnosis.
The Creatinine–Creatine Example: How Lab-Linked Myths Arise
Creatinine is a natural breakdown product of muscle metabolism and a kidney function marker—not a toxic substance. Creatine supplementation can increase creatinine levels without causing kidney damage: creatine spontaneously degrades to creatinine in serum in a dose-dependent, reversible manner. In people with normal kidney function, with adequate hydration, creatine has proven safe long-term (International Society of Sports Nutrition, 2017 position statement).
Creatine protocol: 3–5 g/day, without need for a loading phase; adequate hydration (creatine osmotically draws water into muscle); CKD[G] stage 2+ kidney disease requires physician supervision; CKD[G] stage 1 (normal GFR[G], only protein/blood in urine) is generally safe. While taking creatine, creatinine level alone does not indicate kidney damage—GFR[G] (glomerular filtration[G] rate) is the more informative marker.
This example highlights how a single lab parameter without context is misleading. When interpreting creatinine, muscle mass, diet, creatine use, and physical load must all be considered. This is true for every biomarker.
The Real “Core List”—With Target Values and Doses
This chapter’s promise: the core list. Below are the supplements with the strongest clinical evidence in the metabolic population discussed here. For every supplement: when it’s indicated, what the goal is, what the checkpoint is.
What is NOT generally recommended: multivitamin complexes (except documented deficiency—high-dose vitamin combinations are unnecessary burden; some fat-soluble vitamins, e.g., vitamin A, can be toxic with accumulation); diet supplements (green tea extract, garcinia cambogia—minimal evidence, possible side effects); detox regimens and other non-evidence-based products.
How Do We Evaluate a Supplement’s Effect?
Link every supplement to a measurable target, and a checkpoint. If no documentable effect within 8–12 weeks (in labs or symptoms), discontinuation is justified. The Lifestyle Log and lab trends help recognize if a supplement provides real benefit.
Discuss every supplement with your physician, especially alongside drugs. Regular monitoring—lab trends, symptoms, Lifestyle Log—helps avoid unnecessary or harmful products.
MetSyn lab panel: interpretation thresholds
The table below presents the extended lab panel for evaluation of metabolic syndrome (MetSyn) and insulin resistance[G]. The thresholds are intended for joint interpretation with the treating physician — a single deviant value is not diagnostic but calls for trend assessment (at least 2–3 month intervals). Source: ATP III, IDF, ADA 2024.
| Parameter | Thresholds | Clinical meaning |
|---|---|---|
| HOMA-IR[G] | >2.5 suspected IR; >3.5 clear IR; >5.0 severe IR | Estimate of insulin sensitivity[G] |
| Fasting insulin[G] | >100 pmol/L (>15 mIU/L) | Significant IR indicator |
| HbA1c[G] | 5.7–6.4% prediabetes; ≥6.5% diabetes | 2–3 month average glucose status |
| Fasting glucose | 5.6–6.9 mmol/L (100–125 mg/dL) prediabetes; ≥7.0 mmol/L diabetes | Snapshot — may remain normal long in IR |
| TG/HDL ratio | >3.0 IR surrogate; >5.0 atherogenic dyslipidemia | NHANES-validated IR proxy |
| Triglycerides | ≥1.7 mmol/L (≥150 mg/dL) MetSyn criterion; >5.6 mmol/L pancreatitis risk | Fasting measurement required |
| HDL | men <1.03 mmol/L (<40 mg/dL); women <1.29 mmol/L (<50 mg/dL) | MetSyn criterion |
| Waist circumference | men ≥94 cm, women ≥80 cm (European IDF) | Central obesity criterion |
| Blood pressure | ≥130/85 mmHg | MetSyn criterion |
| hsCRP[G] | <1 mg/L low; 1–3 moderate; >3 high CV risk | Low-grade systemic inflammation |
| ALT | men >40 U/L, women >32 U/L | Suspected NAFLD (hepatic IR) |
| GGT | >40 U/L men, >25 U/L women | Metabolic hepatic load |
| HOMA-β | <50% | Reduced β-cell reserve |
| Adiponectin | <4 µg/mL | Low — elevated IR risk |
| CGM[G] TIR (3.9–10.0 mmol/L) | >70% good / <50% poor control | Time proportion in target zone |
| CGM[G] CV | <33% good | Glucose variability |
For MetSyn IDF diagnosis: central obesity (waist circumference threshold) + at least 2 additional criteria (TG ≥1.7; HDL low; BP ≥130/85; fasting glucose ≥5.6 mmol/L). Repeated every 3–6 months, the full panel shows whether the lifestyle intervention and targeted supplements are actually improving the metabolic state. An isolated change in a single value (e.g., measurement error, acute illness, hydration) can be misleading — the trend matters more than the snapshot.
Summary of 3-day goal: understand that supplements are useful only when targeted and measurably justified, and establish a “core list” containing only proven or indicated supplements.
- Personal supplement list reviewed
- Core list established—each item with indication, dose, and checkpoint
- Unnecessary products discontinued
- CGM[G] data and supplement effects correlated (if CGM[G] available)
- At least 9,200 steps/day
- Daily fluid intake goal minimally 2.2 liters (morning 2×200 ml, daytime minimally 1.4 liters, evening 2×200 ml)
Why doesn’t a supplement replace lifestyle?
- Limited effect: body function is primarily determined by sleep, food quality, movement (Zone 2[G]), and stress management
- Adaptation noise: too many supplements obscure real lifestyle effects and make system understanding harder
- Late vs. early markers: blood glucose is late signal; fasting insulin[G] + HOMA-IR[G] are earlier—formula: fasting insulin[G] × fasting glucose ÷ 22.5; reference: <1.5 normal; >2.5 clinical IR
- Context: a single marker (e.g., creatinine) alone is misleading—muscle mass, diet, and creatine use must be considered
Core List Principles
- Documented deficiency: vitamin D (<50 nmol/L), B12 (metformin[G] users, vegans, PPI users), magnesium (sleep disorder, IR, constipation), iron (ferritin <30 μg/L)
- Specific therapeutic goal: omega-3 (elevated TG, low fish intake), creatine (muscle protection on GLP-1[G] treatment or caloric deficit), psyllium[G] (fiber <20 g/day, slow transit)
- Measurable checkpoint: for every supplement: target value + timing + if no effect within 8–12 weeks → discontinue
What do we measure?
- Fasting insulin[G] and glucose (for HOMA-IR[G] calculation)—every 3 months until goal is reached
- Inflammatory markers (CRP[G], if indicated)
- Stool quality and digestive comfort (effect of fiber supplementation)
- CGM[G] as feedback: pre- vs. post-supplement postprandial[G] profile comparison (if available)
“A supplement does not replace lifestyle. More is not always better. Only take what has a purpose.”
Today, inventory what you currently take. For each product, note: what’s the goal, what’s the dose, how long have you taken it, and have you ever measured its effect?
- Record every supplement in Lifestyle Log
- Note indication and goal for each item—if you don’t know the reason, that’s a sign of needlessness
- Record timing
- 20-minute walk during daytime hours
- Mental task: which one do you not know the exact indication or target for?—these go under scrutiny tomorrow
Today, decide the fate of every item from yesterday: justified (documented deficiency or targeted therapeutic goal) or unnecessary (marketing, habit, uncertainty)? The core list in the chapter is your screening basis.
- Select medically justified supplements
- Discontinue unnecessary products—and note the reason
- Compare CGM[G] and well-being against supplements (if CGM[G] available)
- Step count at least 9,200
- Mental task: which supplement really and measurably improved your well-being or a lab value?—it stays on the core list; note the evidence
Today, stabilize the remaining list: record times, doses, and checkpoints (when and what we measure to prove effect).
- Stabilize supplement timing and dosing—fixed routine reduces decision burden
- Record any side effects
- Keep meal times stable
- Fluid intake 2.2–2.5 liters
- Mental task: what can I safely stop, and what needs lab check-in after 3 months?—this is your core list audit frame
- body weight;
- meal times and contents (N–S);
- post-meal walk (Y/N);
- snacking (Y/N);
- snack contents (list);
- daily protein intake (g);
- energy density[G] (0/+/++);
- NOVA[G] level;
- sleep quality (1–5);
- hunger scale (1–5);
- stress level (1–5);
- step count;
- bedtime / wake time (AC, AD);
- stool Bristol (1–7);
- bloating;
- flare-up (Y/N);
- daily stool frequency;
- fluid intake (l);
- CGM[G] note (AP, optional);
- UltraBiome dose;
- LOT identifier;
The purpose of these 3 days is to eliminate unnecessary supplements, reduce costs, lower side effect risk, and strengthen lifestyle-based weight regulation.
References
[100] Markowiak P, Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017. Link
Review framing the gastrointestinal tract as a complex microbial ecosystem in symbiotic co-evolution with the host. Beneficial bacteria produce nutrients, prevent enteric pathogen infection, and modulate normal immune responses. The review summarizes strategies for modifying the intestinal microbiota to achieve, restore, and maintain favourable ecological balance, including diet, prebiotics, probiotics, and FMT.